ION expands ETF trading capabilities with Tradeweb integration
Director Harpreet Grewal of Penumbra Inc (NYSE:PEN) sold 186 shares of common stock on November 4, 2025, at a price of $227.58, for a total transaction value of $42,329. Since this transaction, Penumbra’s stock has climbed to $264.61, representing a 16.3% increase. According to InvestingPro, the medical device company currently trades above its Fair Value, with a market capitalization of $10.28 billion.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Grewal directly owns 8,516 shares of Penumbra Inc , a portion of which is subject to vesting. Penumbra maintains a "GREAT" financial health score on InvestingPro, with strong profitability (EPS of $4.24) despite trading at a high P/E ratio of nearly 70. Analysts have set price targets ranging from $186 to $350, reflecting mixed opinions about the stock’s current valuation. For investors seeking deeper insights, Penumbra is among 1,400+ companies featured in Pro Research Reports, which transform complex Wall Street data into actionable intelligence.
In other recent news, Penumbra reported strong third-quarter 2025 financial results, with revenue reaching $354.7 million, a 17.8% year-over-year increase, surpassing the forecast of $340.91 million. This performance exceeded consensus estimates, leading the company to raise its 2025 revenue guidance. Penumbra’s thrombectomy segment growth improved to 15% at constant currency, while the U.S. Embolization & Access segment outperformed expectations. The U.S. Thrombectomy revenue grew 19%, supported by a strong 34% growth in venous thromboembolism (VTE).
In light of these results, Needham reiterated its Buy rating on Penumbra, setting a price target of $326.00. Truist Securities also maintained a Buy rating, raising its price target to $312.00, citing the robust VTE growth. Additionally, Evercore ISI adjusted its price target to $286.00, noting the company’s approximately 17% organic revenue growth and a 20.8% increase in the Embolization segment. These developments highlight the company’s positive momentum and the favorable outlook from multiple analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.